+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model

Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model

Human Gene Therapy. Clinical Development 29(2): 90-100

Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30- to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7% of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.

(PDF emailed within 0-6 h: $19.90)

Accession: 065170722

Download citation: RISBibTeXText

PMID: 29869540

DOI: 10.1089/humc.2017.142

Related references

Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model. Human Gene Therapy. Clinical Development 29(2): 101-112, 2018

Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Therapy 9(1): 12-20, January, 2002

Evaluation of intra-articular polysulfated glycosaminoglycan and sodium hyaluronan for treatment of osteoarthritis using an equine experimental model. Proceedings Of The 54th Annual Convention Of The American Association Of Equine Practitioners, San Diego, California, Usa, 6-10: 0-251, 2008

Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Engineering. Part B, Reviews 16(1): 81-92, 2010

Intra-articular delivery of glucosamine for treatment of experimental osteoarthritis created by a medial meniscectomy in a rat model. Journal of Orthopaedic Research 32(2): 302-309, 2014

Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model. International Journal of Pharmaceutics 441(1-2): 285-290, 2013

ScAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Therapy 20(6): 670-677, 2013

Evaluation of intra-articular hyaluronan, sodium chondroitin sulfate and N-acetyl-D-glucosamine combination versus saline (0.9% NaCl) for osteoarthritis using an equine model. Veterinary Journal 197(3): 824-829, 2014

Intra-articular TSG-6 delivery from heparin-based microparticles reduces cartilage damage in a rat model of osteoarthritis. Biomaterials Science 6(5): 1159-1167, 2018

Evaluation of topical diclofenac liposomal cream for treatment of equine osteoarthritis using an equine experimental model. 2007

Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. Arthritis Research and Therapy 15(1): R22, 2015

In vivo human adipose-derived mesenchymal stem cell tracking after intra-articular delivery in a rat osteoarthritis model. Stem Cell Research and Therapy 7(1): 160, 2017

Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation. Drug Delivery and Translational Research 8(5): 1421-1435, 2018

Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clinical Orthopaedics and Related Research 2000(379 Suppl): S273-S287, 2000

Improvement in cartilage following intra-articular injection of TG-C, a cell mediated gene therapy for osteoarthritis. Osteoarthritis and Cartilage 22: S399-S400, 2014